CA-CAVLI-WIRELESS
5.1.2023 15:08:41 CET | Business Wire | Press release
Cavli Wireless, one of the first truly 'IoT ready' cellular module manufacturers, and Qualcomm Technologies. Inc., the world’s leading wireless technology innovator, announced today a strategic collaboration for LTE CAT1 technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005571/en/
Powering the next generation of CAT1.bis IoT with Cavli C16QS Smart Cellular IoT Module (Graphic: Business Wire)
By utilizing the Qualcomm® QCX216 LTE IoT Modem, Cavli Wireless will now be able to utilize the pioneering speed and innovative solutions that Qualcomm Technologies is known for, and deliver the Cavli Hubble IoT stack to customers worldwide. With the C16QS CAT1.bis Cellular IoT module, Cavli Wireless will make IoT adoption seamless & scalable for a wide range of IoT use cases ranging from e-mobility, POS machines, Electric charging stations, TCU, Asset tracking, and so much more.
The Cavli C16QS is an integrated single-mode LTE CAT1.bis Cellular Module based on 3GPP Release 14 comes with integrated eSIM and GNSS. The Cavli C16QS will also offer OEMs implementing IoT to cut down initial hardware costs due to the sub $5 pricing of the module. And further combining the IoT hardware along with Cavli Hubble - The world's most robust IoT connectivity and modem management platform, the C16QS will offer unparalleled value for all industries across all borders.
In addition, under the Hubble Stack Intelligence, the Cavli C16QS can be managed via Hubble Lens, an advanced remote diagnosis feature of the Cavli Hubble Modem Management platform wherein a customer can remotely diagnose, monitor & debug the field device with zero physical intervention, thereby paving the way for the true scaling of IoT.
“Customer samples are available now, and mass production will start in early 2023 at the India facility.”
“The launch of C16QS LTE CAT1.bis cellular IoT module is a new and exciting beginning to our collaboration with Qualcomm Technologies,” said John Mathew, Chief Executive Officer at Cavli Wireless. “We are beyond excited to have our new module be introduced to the global markets, which will be the start of the new era of LTE CAT1 for IoT. This is another big step for Cavli Wireless in moving forward with our vision of democratizing IoT for all.”
About Cavli Wireless
Cavli Wireless designs and manufactures IoT-Ready cellular modules that improve device reliability and expedite development processes for various applications. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users with affordable international data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated
Qualcomm QCX216 LTE IoT Modem is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005571/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom